

Supplementary Table 1. Association of EHOA GWS variants in the individual study populations

rsName	Chr	Pos_build38	Effect	Other	Freq (%)	P_value_GWS_t				P_bonferron	Iceland (N = 918 cases / 109,249 controls)				UK Biobank (N = 63 cases / 430,875 controls)				The Netherlands (N = 139 cases / 5,102 controls)				Spain (N = 218 cases / 164 controls)				USA (N = 145 cases / 5,308 controls)				
						P_value		t	P_threshold		P _{het}	I2	P value	OR	EA	Info	P value	OR	EA	Info	P value	OR	(%) EA	Info	P value	OR	(%) EA	Info			
						Allele	EA	OR																							
rs17013495	chr4	87885460	C	T	42.7	8.4E-14	0.72	1.2E-09	3.5E-06	0.18	36.9	2.5E-11	0.70	38.7	1.000	0.71	1.07	43.5	0.999	0.042	0.76	43.0	0.995	5.2E-03	0.60	45.9	0.987	0.020	0.71	42.3	0.990
rs11243284	chr6	8945086	C	T	29.8	4.2E-11	1.35	4.0E-10	5.2E-03	0.67	0	2.9E-08	1.35	29.5	1.000	0.33	1.20	30.3	1.000	0.15	1.22	29.7	0.987	0.011	1.71	29.7	0.817	0.018	1.47	30.0	0.867
rs1800801	chr12	14885854	T	C	39.0	3.6E-13	1.37	2.4E-09	7.5E-06	0.17	38.0	5.0E-07	1.30	37.2	1.000	8.3E-04	1.84	37.8	0.999	7.1E-05	1.70	37.4	1.000	0.14	1.29	45.1	0.989	0.026	1.38	37.3	0.988
rs11631127	chr15	57977811	G	C	47.8	7.1E-18	0.69	4.0E-10	8.9E-10	0.59	0	2.3E-11	0.70	42.4	1.000	0.25	0.81	46.5	1.000	8.4E-05	0.60	47.3	0.998	0.058	0.70	55.8	0.995	5.6E-04	0.61	47.1	0.994

Supplementary Table 2. Association of EHOA variants with EHOA under additive, recessive and full genotype models

Variant[allele]	Chr	Additive model			Recessive model			Genotype specific model						
								Heterozygotes			Homozygotes			
		OR (95% CI)	P value	P _{het}	OR (95% CI)	P value	P _{het}	OR (95% CI)	P value	P _{het}	OR (95% CI)	P value	P _{het}	P model
rs17013495[T]	chr4	1.395 (1.279-1.522)	8.77E-14	0.17	1.600 (1.346-1.901)	9.64E-08	0.16	1.342 (1.098-1.641)	0.0041	0.48	2.011 (1.630-2.481)	7.07E-11	0.63	0.289
rs11243284[C]	chr6	1.354 (1.237-1.482)	4.22E-11	0.67	1.674 (1.387-2.022)	8.47E-08	0.41	1.307 (1.147-1.491)	6.27E-05	0.77	1.773 (1.457-2.157)	1.07E-08	0.66	0.446
rs1800801[T]	chr12	1.368 (1.257-1.488)	3.55E-13	0.17	1.848 (1.594-2.143)	3.86E-16	0.14	1.151 (1.002-1.323)	0.047	0.87	2.012 (1.705-2.373)	1.09E-16	0.34	0.0011
rs11631127[C]	chr15	1.456 (1.337-1.587)	7.15E-18	0.59	1.608 (1.376-1.880)	2.68E-09	0.45	1.320 (1.095-1.591)	0.0036	0.42	2.089 (1.726-2.528)	3.69E-14	0.48	0.241

Association of the four EHOA variants with EHOA is shown for the additive model, the recessive model, and for the full model evaluating risk at the heterozygous genotypes and homozygous genotypes. The effect allele of each variant is shown within square brackets, with the odds ratio (OR) with 95% confidence interval (CI), the P value, and the heterogeneity P value (P_{het}) for each model, and the P value (P model) for deviation from the additive model.

Supplementary Table 3. Association of rs1800801 in 5'UTR of MGP with hand osteoarthritis subtypes under additive, recessive and full genotype model

Phenotype	N cases / N controls	Additive model			Recessive model			Genotype specific model						
								Heterozygotes			Homozygotes			
		OR (95% CI)	P value	Phet	OR (95% CI)	P value	Phet	OR (95% CI)	P value	Phet	OR (95% CI)	P value	Phet	P model
Erosive hand OA	1,484 / 550,680	1.368 (1.257-1.488)	3.6E-13	0.17	1.848 (1.594-2.143)	3.9E-16	0.14	1.151 (1.002-1.323)	0.047	0.87	2.012 (1.705-2.373)	1.1E-16	0.34	0.0011
Finger OA	7,871 / 608,869	1.143 (1.099-1.188)	1.5E-11	0.026	1.258 (1.173-1.349)	1.1E-10	0.035	1.103 (1.037-1.173)	0.0017	0.60	1.349 (1.242-1.464)	1.0E-12	0.031	0.12
Thumb OA	9,865 / 623,814	1.066 (1.031-1.103)	1.6E-04	0.28	1.064 (0.999-1.133)	0.055	0.22	1.108 (1.052-1.166)	1.0E-04	0.44	1.129 (1.050-1.214)	0.0010	0.19	0.056
Hand OA	14,841 / 626,618	1.080 (1.050-1.111)	8.4E-08	0.081	1.132 (1.074-1.193)	3.31E-06	0.059	1.073 (1.027-1.120)	0.0016	0.34	1.181 (1.112-1.254)	6.8E-08	0.08	0.19

Association of the rs180081[T] with hand osteoarthritis subtypes is shown for the additive model, the recessive model, and for the full model evaluating risk at the heterozygous genotypes and homozygous genotypes. The odds ratio (OR) with 95% confidence interval (CI), the P value, and the heterogeneity P value (Phet) is shown for each model, and the P value (P model) for deviation from the additive model. The finger, thumb and hand OA analysis included data from Iceland, US, UK, and The Netherlands, whereas all datasets were included in the erosive hand OA analysis.

Supplementary Table 4. EHOA variants, or their correlated variants, are located in regions defined as candidate cis-regulatory elements by ENCODE project (screen.encodeproject.org).

cCRE annotation:	GWAS association, lead sequence variant for each signal			
	rs17013495 (chr4:87885460) LD class = 68	rs11243284 (chr6:8945086) LD class = 17	rs1800801 (chr12:14885854) LD class = 107	rs11631127 (chr15:57977811) LD class = 155
DNase-H3K4me3				chr15:58008570:SG
Promoter-like sequence (PLS)				chr15:58065219:IG
Promoter-like sequence (PLS)-CTCF-bound			chr12:14885854:SG, chr12:14834162:SG, chr12:14834298:SG, chr12:14836364:SG, chr12:14851053:SG, chr12:14851097:IG,	
Enhancer-like sequence, distal (dELS)	chr4:87868563:SG, chr4:87868643:SG	chr6:8948008:SG, chr6:8948226:SG	chr12:14899824:SG, chr12:14899901:SG, chr12:14900018:SG, chr12:14910656:SG, chr12:14911149:IG, chr12:14911328:SG, chr12:14911429:SG, chr12:14847029:SG,	chr15:58040343:SG, chr15:58040385:SG
Enhancer-like sequence, distal (dELS)-CTCF-bound	chr4:87863666:SG, chr4:87885460:SG	chr6:8949691:SG	chr12:14847226:SG, chr12:14854918:IG, chr12:14901082:SG	chr15:57923529:SG
Enhancer-like sequence, proximal (pELS)			chr12:14839301:SG, chr12:14840674:SG, chr12:14840920:SG, chr12:14883768:SG	chr15:58063976:IG, chr15:58064657:SG
<u>Enhancer-like sequence, proximal (pELS)-CTCF bound</u>				chr15:58064164:SG

The variants are shown by their position in Build38, with SG ending for SNPs and IG for indels

Supplementary Table 6. Co-localisation of EHOA variants and expression of genes at the EHOA loci (eQTL)

EHOA variants	chr:pos(hg38)	EA / OA	Freq% EA	OR	Gene	Tissue	eQTL variant	r ²	EA / OA	Freq% EA	Effect	P value	Source	# individuals/tissue	COLOC PP3	COLOC PP4	
rs17013495	chr4:87885460	T/C	59.6	1.4	SPP1	Spleen	rs4693198	0.91	C/T	59.6	-0.48	1.1E-09	GTEX v8	227	0.12	0.88	
						"	Esophagus – Mucosa	rs4693897	0.91	G/T	59.5	-0.32	1.4E-08	GTEX v8	497	1.00	0.00
						"	Whole blood	rs12644436	0.91	G/A	59.4	-0.18	9.0E-09	GTEX v8	670	1.00	0.00
						Lung	rs11614330	0.98	T/C	36.9	-0.19	5.9E-13	GTEX v8	515	0.09	0.91	
rs1800801	chr12:14885854	T/C	37.2	1.37	MGP	"	Thyroid	rs4581512	0.95	T/G	37.4	-0.17	3.1E-08	GTEX v8	574	0.05	0.95
						"	Adipose	rs9668569	0.91	T/C	37.2	-0.53	2.8E-22	deCODE	770	0.08	0.92
						"	Blood*	rs11056199	0.89	C/A	39.9	0.40	6.9E-226	deCODE	17,940	1.00	0.00
						Cultured fibroblasts	rs3742961	0.93	C/T	60.2	-0.30	9.0E-11	GTEX v8	483	0.14	0.86	
rs11631127	chr15:57977811	C/G	57.6	1.46	ALDH1A2												

Data is shown for datasets in GTEX and deCODE genetics. For each variant the gene whose expression is correlated with the erosive variants is shown (Gene), the tissue (Tissue), the top expression variant (eQTL variant), the correlation between the top expression variant and the erosive variant (r^2), the effect allele (EA) and the other allele (OA) of the variants, the frequency of their effect allele (Freq% EA), the effect on transcription in standard deviation (Effect), the P value of the expression correlation, the source of data (Source), and the number of individuals in each analysis (# individuals/tissue). The position of the erosive variants are shown in build 38, and the OR of the association with erosive osteoarthritis. PP3 is the posterior probability for two independent signals, and PP4 is the posterior probability for one shared signals using COLOC (Giambartolomei et al, PLoS genetics. 2014;10(5):e1004383)

* The expression of MGP in blood is very low but the direction of effect is consistent with that reported by den Hollander, W. et al, 2017.

Supplementary Table 7. Co-localisation of the EHOA associated variants and levels of proteins in plasma (cis-pQTL)

Erosive variants	chr:pos(hg38)	EA / OA	Freq% EA	OR	Gene	Protein	pQTL variant	r^2	EA / OA	Freq% EA	Effect	P value	COLOC PP3	COLOC PP4	Comment
rs17013495	chr4:87885460	T/C	59.6	1.396	SPP1	Osteopontin	rs990862	0.80	T/C	65.9	-0.063	1.8E-13	1.00	0.00	Five independent cis-signals for SPP1, and 2 independent trans signals. Rs990862 explains 5% of the variance explained by the pQTLs
rs1800801	chr12:14885854	T/C	37.2	1.37	MGP	Matrix Gla Protein	rs7294636	0.99	A/G	37.4	-0.250	8.3E-111	0.12	0.88	Two independent cis-signals for the MGP protein (in opposite directions), and 6 trans signals. Rs12307494 explains 72% of the variance explained by the pQTLs.

Data is based on proteins measured in plasma from 35,339 in Iceland (deCODE genetics) using the Somalogic platform. The top variant that correlates with the levels of the protein (Protein) and its encoding gene (Gene) in plasma (pQTL variant) is shown, and the correlation between the top pQTL variant and the erosive variant (r^2), the effect allele (EA) and the other allele (OA) of the variants, the frequency of their effect allele (Freq% EA), the effect on protein levels in standard deviation (Effect), and the P value of the protein level-variant correlation. The position of the erosive variants are shown in build 38 (chr:pos(hg38)), and the odds ratio (OR) of the association with erosive osteoarthritis. PP3 is the posterior probability for two independent signals, and PP4 is the posterior probability for one shared signals using COLOC (Giambartolomei et al, PLoS genetics. 2014;10(5):e1004383)

STOMACH_MUSCLE	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14894016:SG), WBP11 (chr12:14894016:SG)
SUBSTANTIA_NIGRA	ART4 (chr12:14835521:SG, chr12:14840214:SG), MGP (chr12:14840729:SG, chr12:14894016:SG)
SUPERIOR_TEMPORAL_GYRUS	MGP (chr12:14894016:SG)
T17_CELL	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG)
TEMPORAL_LOBE	ART4 (chr12:14835521:SG), MGP (chr12:14894016:SG)
TESTIS	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14847029:SG, chr12:14894016:SG), WBP11 (chr12:14894016:SG)
THORACIC_AORTA	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG, chr12:14844512:SG, chr12:14847029:SG), MGP (chr12:14847029:SG, chr12:14854918:IG, chr12:14879684:SG, chr12:14879827:SG, chr12:14879925:IG, chr12:14879926:SG, chr12:14890950:SG, chr12:14890963:SG, chr12:14894016:SG, chr12:14897475:SG, chr12:14897803:SG, chr12:14901082:SG)
THYROID_GLAND	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), H2A (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14844512:SG, chr12:14847029:SG, chr12:14854918:IG, chr12:14894016:SG)
TIBIAL_ARTERY	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14894016:SG)
TIBIAL_NERVE	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14890950:SG, chr12:14890963:SG, chr12:14894016:SG, chr12:14901082:SG)
TONGUE	MGP (chr12:14854918:IG, chr12:14894016:SG)
TRANSVERSE_COLON	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14894016:SG), WBP11 (chr12:14894016:SG)
TROPHOBLAST	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG, chr12:14851053:SG, chr12:14851097:IG), MGP (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG, chr12:14840974:SG, chr12:14840974:SG, chr12:14854918:IG, chr12:14901082:SG)
TROPHOBLAST_DERIV	ART4 (chr12:14835521:SG, chr12:14851053:SG, chr12:14851097:IG)
TRUNK_MUSCLE	MGP (chr12:14847029:SG, chr12:14854918:IG, chr12:14894016:SG, chr12:14897475:SG, chr12:14897803:SG), ART4 (chr12:14847029:SG)
TUBULE_CELL	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG)
UMBILICAL_CORD	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14894016:SG, chr12:14897475:SG, chr12:14897803:SG)
UMBILICAL_VENOUS_ENDOTHELIAL_CELL	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG, chr12:14879925:SG, chr12:14879926:SG, chr12:14894016:SG), WBP11 (chr12:14847029:SG, chr12:14894016:SG)
URINARY_BLADDER	ART4 (chr12:14847029:SG), MGP (chr12:14847029:SG, chr12:14894016:SG, chr12:14901082:SG), WBP11 (chr12:14894016:SG)
UROTHELIUM_CELL	ART4 (chr12:14835521:SG, chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG)
UTERUS	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), ALDH1A2 (chr15:58061348:SG)
VAGINA	ART4 (chr12:14840136:SG, chr12:14840214:SG, chr12:14840505:SG, chr12:14840674:SG, chr12:14840920:SG), MGP (chr12:14840136:SG, chr12:14851053:SG, chr12:14851097:IG), MGP (chr12:14847029:SG, chr12:14879684:SG, chr12:14879827:SG, chr12:14879925:IG, chr12:14879926:SG, chr12:14890950:SG, chr12:14890963:SG, chr12:14894016:SG, chr12:14901082:SG)
VILLOUS_MESENCHYME_FIBROBLAST	MGP (chr12:14854918:IG)

The variants are shown by their position in Build38, with SG ending for SNPs and IG for indels

Supplementary Table 9. Enrichment-Analysis: EHOA association signals are nominally enriched within regulatory regions specific for vascular/endothelial cell types.

Annotation	Number of overlapping GWAS loci	P-value	Expected intersection (95%CI)	Observed intersection (95%CI)	Enrichment (95%CI)
Vascular-endothelial	4	0.011	0.35 (0-0.75)	1 (1.00-1.00)	2.84 (2.84-2.84)
Pulmonary development	3	0.06	0.31 (0-0.75)	0.75 (0.25-1)	2.44 (0.813-3.25)
Musculoskeletal	3	0.27	0.50 (0-1)	0.75 (0.25-1)	1.52 (0.505-2.02)
Digestive	3	0.29	0.51 (0.25-1)	0.75 (0.369-1)	1.47 (0.723-1.96)
Myeloid-erythroid	3	0.41	0.57 (0-1)	0.75 (0.369-1)	1.32 (0.65-1.76)
StromalA	1	0.59	0.21 (0-0.5)	0.25 (0-0.75)	1.21 (0-3.61)
Renal-cancer	2	0.69	0.47 (0-0.75)	0.5 (0-1)	1.06 (0-2.12)
Organ development-renal	2	0.72	0.50 (0-1)	0.5 (0-1)	0.99 (0-1.99)
StromalB	3	0.76	0.73 (0.25-1)	0.75 (0.25-1)	1.03 (0.342-1.37)
Lymphoid	2	0.52	0.60 (0.25-1)	0.5 (0-1)	0.83 (0-1.66)
Primitive-embryonic	3	0.55	0.82 (0.5-1)	0.75 (0.25-1)	0.91 (0.304-1.22)
Placental-trophoblast	2	0.48	0.63 (0.25-1)	0.5 (0-1)	0.80 (0-1.6)
Cardiac	1	0.51	0.38 (0-0.75)	0.25 (0-0.75)	0.66 (0-1.99)
Cancer-epithelial	1	0.47	0.43 (0-1)	0.25 (0-0.75)	0.58 (0-1.75)
Neural	2	0.30	0.71 (0.25-1)	0.5 (0-1)	0.70 (0-1.41)
Tissue-invariant	0	0.034	0.52 (0-1)	0 (0-0)	0 (0-0)

15q21.3-ALDH1A2	rs11631127	EHOA	C	G	4.7E-07	0.95	Knee osteoarthritis	PMID:30664745	24,955	403,124	GCST007090	
15q21.3-ALDH1A2	rs4775006	Correlated GWS	A	C	0.74	3.0E-22	Brain region volumes [X4th ventricle]	PMID:31676860	19,629	GCST009518_4		
15q21.3-ALDH1A2	rs4775006	Correlated GWS	A	C	0.74	1.0E-18	Subcortical volume (min-P)	PMID:32665545	26,502	GCST010698		
15q21.3-ALDH1A2	rs4775006	Correlated GWS	A	C	0.74	2.0E-18	Brain morphology (min-P)	PMID:32665545	26,502	GCST010699		
15q21.3-ALDH1A2	rs3204689	Correlated GWS	C	G	0.65	1.0E-11	Osteoarthritis (hand, severe)	PMID:24728293	78,162	GCST002410		
15q21.3-ALDH1A2	rs66725070	Correlated GWS	G	GACAT	0.73	3.0E-10	Barrett's esophagus	PMID:27527254	23,326	GCST003738		
15q21.3-ALDH1A2	rs4775006	Correlated GWS	A	C	0.74	8.4E-10	1.06	Knee osteoarthritis	PMID:30664745	403,124	GCST007090	
15q21.3-ALDH1A2	rs8033270	Correlated GWS	C	G	0.64	9.0E-10	0.84	Polyarthrosis		149,831	FINNGEN_R5_M13_ARTHROSIS_POLY	
15q21.3-ALDH1A2	rs4775006	Correlated GWS	A	C	0.74	7.1E-09	1.03	Knee pain pain type(s) experienced in last month		360,391	NEALE2_6159_7	

Association results assessed by UKBiobank associations at deCODE genetics, and by Open Targets Genetics (<https://genetics.opentargets.org/>) which summarizes association data for the variants in public datasets (UK Biobank, FinnGen, and GWAS Catalog). The site was accessed on February, 23rd, 2022. The look-up results for the EHOA variants are shown directly, and for correlated variants ($r^2 > 0.60$) that have been reported to associate with a given trait at a GWS level in the Open Targets Genetics database. The effect allele, the other allele, r^2 with EHOA variant at the locus, P value and beta or odds ratio (OR) are shown for each trait, along with publication ID, number of cases and/or overall study sample, and the Study ID. Associations with $P < 1e-6$ are shown.

*We note that this association is most likely due to a missense variant in ART4 which changes the binding of the Somalogic probe to the plasma protein

Supplementary Table 11. Association of EHOA variants with bone density, grip strength and urate levels

Variant	Chr	EA	NEA	FN_BMD (N = 107,310)		LS_BMD (N = 106,228)		eBMD (N = 398,823)		Grip strength (N = 427,745)		Urate (N = 411,640)	
				P value	Effect	P value	Effect	P value	Effect	P value	Effect	P value	Effect
rs17013495	chr4	T	C	4.9E-04	0.015	1.6E-09	0.028	0.89	0	1.9E-05	-0.010	8.5E-21	0.018
rs11243284	chr6	C	T	0.082	-0.008	0.0035	-0.015	0.78	-0.001	2.7E-03	-0.007	0.76	0.001
rs1800801	chr12	T	C	1.4E-05	-0.019	8.9E-08	-0.025	1.4E-09	-0.015	5.0E-35	-0.029	0.036	-0.004
rs11631127	chr15	C	G	0.59	-0.002	8.3E-07	0.023	0.21	-0.003	9.8E-10	-0.014	0.95	0

Results for eBMD, grip strength and urate levels are from the UK Biobank resource, run at deCODE genetics. Results for FN (femoral neck) and LS (lumbar spine) BMD are derived from our unpublished meta-analysis of BMD in Iceland, UK Biobank, and the publicly available GEFOS consortium (Zheng et al, Nature, 2015).

Supplementary Table 12. Significant association of EHOA polygenic risk score with phenotypes in UK biobank

Phenotype	P value	Effect /OR	N cases	N controls	N overall	nR2
Grip strength (mean, age, sex, height adj.)	6.0E-41	-0.022			427,745	0.00048
Other arthrosis (ICD10:M19)	4.8E-29	1.05	73,440	357,607		0.00048
Any OA	2.1E-19	1.04	103,173	327,874		0.00029
Polyarthrosis (ICD10:M15)	4.9E-17	1.08	12,326	418,612		0.00072
Hand OA	4.7E-16	1.15	3,416	427,631		0.00175
Pain due to OA	7.5E-14	1.05	44,262	98,258		0.00053
Pain in hands in last three months	2.8E-13	1.11	5,766	64,039		0.00174
Heberden nodes with arthropathy	1.1E-12	1.30	758	428,428		0.00464
Finger OA	1.3E-13	1.29	834	428,352		0.00407
Other arthritis (ICD10:M13)	6.3E-10	1.04	33,303	397,744		0.00021
Operation of joint of finger (OPCS:Z83)	1.3E-09	1.10	4,289	426,758		0.00082

A PRS for EHOA was generated from the Icelandic, the Dutch, the US and Spanish EHOA datasets. The MHC region was excluded from the EHOA PRS. The results are shown from a scan of diverse phenotypes derived from the UK Biobank. Significance was set as $P < 1.0 \times 10^{-5}$, accounting for 5,000 main phenotypes. nR2 is the Nagelkerke's correlation coefficient.

HipOA	rs798756	T	C	19.4	68	knee,hip,all	0.93	2.2E-09	0.85	0.0044
HipOA	rs4073717	T	G	20.1	74	hip	0.94	2.5E-09	0.90	0.05
HipOA	rs17677724	T	C	16.1	72	hip,all	1.07	3.5E-09	1.12	0.05
HipOA	rs1809889	T	C	28.0	20	hip	1.06	3.6E-09	1.07	0.17
HipOA	rs10983775	T	C	54.2	96	hip	0.95	4.7E-09	0.99	0.80
HipOA	rs66989638	A	G	12.7	48	hip	1.08	4.8E-09	1.00	0.97
HipOA	rs7862601	A	G	62.4	94	hip	0.94	6.2E-09	0.94	0.15
HipOA	rs7222178	A	T	19.5	40	hip	1.07	7.4E-09	1.01	0.82
HipOA	rs10940168	A	G	39.4	76	hip	0.95	7.7E-09	1.01	0.76
HipOA	rs6855246	A	G	92.8	64	hip,all	0.90	7.9E-09	1.08	0.53
HipOA	rs10465114	A	G	22.0	98	hip	1.06	9.0E-09	1.01	0.89
AIIOA	rs13107325	T	C	7.1	64	hip,all	1.08	3.2E-17	0.94	0.65
AIIOA	rs3771501	A	G	46.8	52	hand, thumb, hip, all	1.04	4.0E-15	1.16	6.4E-04
AIIOA	rs1913707	A	G	60.5	66	hip,all	1.03	1.4E-12	1.06	0.16
AIIOA	rs2425061	A	G	62.8	53	knee,all	1.03	2.1E-12	0.94	0.14
AIIOA	rs216175	A	C	82.8	37	all	1.04	2.7E-12	1.09	0.11
AIIOA	rs2622873	T	C	88.0	1	hip,all	1.05	4.2E-11	1.03	0.66
AIIOA	rs10405617	A	G	31.9	43	knee,all	1.03	9.3E-11	1.22	1.5E-05
AIIOA	rs12901372	C	G	52.7	32	all	1.03	1.0E-10	1.07	0.10
AIIOA	rs11731421	A	G	34.6	68	knee,hip,all	1.03	1.9E-10	1.19	1.0E-04
AIIOA	rs75621460	A	G	2.6	44	all	1.10	1.1E-09	1.06	0.65
AIIOA	rs4979341	T	C	27.5	92	knee,all	1.03	1.4E-09	1.04	0.41
AIIOA	rs12667224	A	G	52.0	85	all	0.97	1.7E-09	0.96	0.30
AIIOA	rs62242105	A	G	33.1	62	hip	0.97	2.9E-09	1.01	0.79
AIIOA	rs201194999	T	C	30.1	69	all,spine	0.88	3.1E-09	0.57	0.27
AIIOA	rs62182810	A	G	54.4	49	all	1.03	3.8E-09	1.07	0.15
AIIOA	rs11729628	T	G	23.9	65	all	0.97	4.7E-09	0.91	0.05
AIIOA	rs14011795	A	G	50.0	39	all	1.03	6.2E-09	1.03	0.47
AIIOA	rs10831476	A	C	81.1	17	hip,all	1.03	7.8E-09	1.01	0.82
AIIOA	rs17677555	C	G	25.6	72	hip,all	1.03	1.1E-08	1.08	0.13

The Genetics of Osteoarthritis (GO) consortium data is from Boer et al, Cell, 2021. OR (odds ratio) and P values and ORs are shown for the respective osteoarthritis (OA) phenotypes in the GO consortium data. The OA phenotypes that are significantly associated with the respective signal in GO are listed under the column "Associated GWS OA phenotypes" (often represented by a different, but highly correlated, variant).